Feasibility Study for the Long-Term Management of Refractory Hyperkeratotic Eczema with Calcipotriol and Betamethasone Dipropionate (Daivobet^®), Viaminate and Concomitant Conventional Therapies: A Retrospective Study

Figures & data

Table 1 Baseline Demographics and Clinical Characteristics

Demographics	Mean (SD)/Median	Number (%)
Age (years)	47.28 (11.05)
Sex
Male		40 (65.6)
Female		21 (34.4)
Disease duration (years)	3
Disease severity
Moderate		49 (80.3)
Severe		12 (19.7)
Disease location
Palms		18 (29.5)
Plantaris		17 (27.9)
Lower legs		15 (24.6)
Feet and ankles		11 (18.0)
Secondary symptoms
Severe pruritus
No		13 (21.3)
Yes		48 (87.7)

Figure 1 Showing linear changes of loss of keratinization from baseline to after treatment.

Table 2 Assessment of Treatment Period for Moderate and Severe Disease

Variable	Moderate	Severe	P-value	95% CI
Loss of keratinization period (weeks)	3.9±1.9	10.8±1.0	<0.01	−8.0 to −5.7
Total treatment period (weeks)	10.6±4.3	20.3±3.6	<0.01	−12.4 to −7.0

Table 3 Efficacy Outcomes

Secondary Outcomes		Treatment n (%)		P-value
		Before	After
Had pruritus		54 (88.5)	7 (11.5)	<0.01

Table 4 Post Hoc Analysis from Week 24 to Week 36

Criteria	Categories	Disease Severity n (%)		P-value
		Moderate	Severe
IGA	< 2 Reduction	11 (22.4)	4 (33.3)	0.467
	> 2 Reduction	38 (77.6)	8 (66.7)
POEM	< 90	7 (14.3)	2 (16.7)	1.00
	> 90	42 (85.7)	10 (83.3)